Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: A clinical update

Annals of the Rheumatic Diseases

Volumn 59, Issue SUPPL. 1, 2000, Pages

  Davis, M W ^a   Feige, U ^a   Bendele, A M ^b   Martin, S W ^a   Edwards III, C K ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; HYDROXYCHLOROQUINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MACROGOL; METHOTREXATE; RECOMBINANT METHIONYL SOLUBLE TUMOR NECROSIS FACTOR 1 RECEPTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEADACHE; HUMAN; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE II; HUMANS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 0033762622     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): Novel high affinity TNF receptor designed for chronic inflammatory diseases
2. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: Correlation of plasma levels with efficacy
3. Combination benefit of PEGylated soluble tumor necrosis factor receptor type 1 (PEG sTNF-R1) and dexamethasone or indomethacin in adjuvant arthritic rats
4. Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats
5. Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon
6. Development of a novel, non-immunogenic soluble human TNF receptor type I construct that blocks pathological effects of systemic TNF-α in the juvenile papio
7. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats
8. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis
9. Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor
10. A phase 1 study of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-R1[p55]) in subjects with rheumatoid arthritis (RA)
11. The pharmacokinetics of subcutaneous injections of PEGylated recombinant methionyl human soluble tumor necrosis factor-type I receptor (PEG sTNF-R1) in subjects with active rheumatoid arthritis
12. Non-immunogenicity of a PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-R1[p55])
13. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis
14. Combination benefit of treatment with recombinant human interleukin-1 receptor antagonist (IL-1ra) and pegylated recombinant human soluble tumor necrosis factor receptor type I (PEG sTNF-RI) in animal models of rheumatoid arthritis
15. Combining anti-IL-1 and anti-TNF treatments provides better efficacy in rat adjuvant arthritis than does either agent alone